HCPCS Level II code J0584 denotes a 1 mg unit of burosumab-twza injection, a targeted monoclonal antibody therapy used in disorders of phosphate metabolism. Nationally, accurate reporting of J0584 matters for proper reimbursement, utilization tracking of high-cost biologics, and clinical care coordination for patients requiring parenteral therapy.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and coding context for J0584, national reimbursement and coverage considerations, common places of service for administration, and benchmarking insights where available. The publication highlights payer coverage patterns, prior authorization and medical necessity themes affecting access to burosumab, and coding best practices for clean claims submission.

This summary provides clinical context for when J0584 is used, outlines what documentation typically supports medical necessity, and summarizes the components of a service line involving an injectable biologic. Data not provided in the input (for example, specific payer policy details, ICD-10 pairings, and related codes) are identified as unavailable. The content is intended for national audiences including coding professionals, revenue cycle staff, and clinical administrators evaluating billing and coverage for burosumab therapy.